Genentech, OSI shares hit by lung-cancer study
Shares of Genentech Inc. and OSI Pharmaceuticals fell Monday after the companies reported disappointing results from a study that tested Genentech’s top-selling oncology drug Avastin with OSI’s Tarceva in the treatment of advanced lung cancer.
This entry was posted on Monday, October 6th, 2008 at 1:10 pm and is filed under Research, Treatment. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.